Global Pharmaceutical Company Licenses Ajinomoto’s Corynex™ Recombinant Protein Expression System Following Successful Proof-of-Concept Ajinomoto Enables Pharma to Research and Develop Difficult to Express Proteins Business Wire RALEIGH, N.C. -- March 5, 2013 Ajinomoto North America, Inc. today announced a top-tier, global pharmaceutical company has licensed its Corynex^TM Recombinant Protein Expression System. The pharma assessed the Technology with a number of recombinant proteins. Based upon a successful proof-of-concept, the company has entered a full licensing agreement that allows for the in-house use of Ajinomoto’s proprietary Corynex^TM Expression. Corynex^TM uses the gram-positive Corynebacterium glutamicum to reduce purification steps, lower costs, and increase yield. Corynex^TM does not require cell lysis or protein refolding, eliminating the need for endotoxin removal steps. The system also speeds production through a fast-growing bacterial model, shorter fermentation run to produce proteins and cheaper bacterium medium cost. Ajinomoto was initially tasked with expressing a viable level of a series of proteins for the global pharma, several of which had prior low levels of expression when using traditional microbial expression platforms. Preliminary results showed that with the development of protease deficient strains, Ajinomoto successfully expressed over 50% of the proteins within the study. This high success rate showcased the market potential for the Corynebacterium glutamicum expression method – especially with proteins that traditional expression systems had struggled to express. “We are pleased to extend a licensing agreement with a top-tier pharmaceutical company to build upon our initial successful proof-of-concept efforts,” Joel White, business manager of Ajinomoto, stated. To read more about Ajinomoto’s successes and lessons learned using its Corynex^TM Recombinant Protein Expression System, please visit www.corynex.com. In addition to two case studies, you can download a related whitepaper, “Speeding and Simplifying Recombinant Protein Production ” and view video animation of the expression and export of recombinant proteins from Corynebacterium glutamicum. Companies looking to bring this proven expression system in-house for the development of their own proprietary proteins should contact Joel White directly at firstname.lastname@example.org or 919.723.2116. About Ajinomoto North America, Inc. Ajinomoto is the leading global supplier of pharmaceutical and research-grade amino acids. Leveraging its unrivaled foundation of more than 50 years experience identifying, refining, and marketing amino acids, Ajinomoto North America, Inc. continues to innovate and set new industry standards for manufacturing and related services within the fermentation and expression fields. Building on its legacy, Amino Acid Technologies has transitioned the same level of quality and performance into new core competencies in the areas of recombinant protein expression and peptide synthesis. These new processes enable pharmaceutical and biotech companies to develop high-quality products that were previously thought to be too complicated or expensive to produce. Ajinomoto North America, Inc. is a wholly-owned subsidiary of Ajinomoto Co., Inc. For more information, please refer to http://www.ajiaminoscience.com/Default.aspx##. Contact: Crossroads Public Relations for Ajinomoto North America, Inc. Molly Thompson, 919-821-2822 mobile: 919-605-0022 email@example.com
Global Pharmaceutical Company Licenses Ajinomoto’s Corynex™ Recombinant Protein Expression System Following Successful Proof
Press spacebar to pause and continue. Press esc to stop.